Navigation Links
Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands
Date:9/21/2009

MORRISTOWN, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that G. Frederick Wilkinson has joined the Company as Executive Vice President, Global Brands. In this newly expanded position Mr. Wilkinson will be responsible for all aspects of the Company's global brand pharmaceutical business, including brand product development, global sales and marketing and coordinating brand product business development activities. In addition, Mr. Wilkinson will oversee Watson's biologic development efforts. Mr. Wilkinson will report directly to Paul Bisaro, President and Chief Executive Officer.

"Fred returns to Watson with an extraordinary record of accomplishments having built a successful brand products business at Duramed Pharmaceuticals, the brand business of Barr Pharmaceuticals, particularly in the area of women's healthcare," said Paul Bisaro, Watson CEO. "We will look to Fred to further strengthen our US brand business, which includes a strong product portfolio supported by the recent launches of RAPAFLO(R) and Gelnique(R)."

"Fred's global experience will also be invaluable as we seek to maximize opportunities for our brand portfolio in new markets that will result from the successful acquisition of Arrow Group, which is expected to close this fall," Bisaro added. "Finally, Fred's experience in biologics, including expansion of Barr's biopharmaceutical production capabilities, development of a pipeline of early stage projects, and his work to shepherd Barr's initial biologics vaccine product through the FDA clinical development process, will enable him to effectively guide our efforts in becoming a leader in the generic biologics area."

Most recently, Mr. Wilkinson served as President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., the proprietary products subsidiary of Barr Pharmaceuticals, Inc. He joined Duramed in 2006 and had responsibility for the Company's successful expansion of Duramed's female healthcare product franchise and pipeline, and for managing Barr's biologics initiatives. Prior to joining Duramed Pharmaceuticals, Mr. Wilkinson served as President and Chief Executive Officer of Columbia Laboratories since 2001. From 1996 to 2001, Mr. Wilkinson was Senior Vice President and Chief Operating Officer of Watson Pharmaceuticals. Prior to joining Watson, he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions of increasing responsibility.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).

For press releases and other company information, visit the Watson Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University ... printing facility among higher education institutions in Hong Kong to support teaching, learning and ... the range and quantity of facilities in Hong Kong. , With an area ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is a group ... mental health struggles. The Alive team uses advanced behavioral sciences treatment modalities to ... with a mental health struggle is based on 10 modalities of treatment ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... category of International Trade, the UK’s most prestigious award for business success. ... 95% of total revenues and has grown by a total of 400% over ...
(Date:4/21/2017)... ... , ... BrightStar Care Salt Lake City, a home care agency that also ... has appointed Rex Wheeler as its new Director of Business Development. “This partnership helps ... ability to provide quality care to the community,” said Tammara Brown, owner of BrightStar ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Viverae ® ... to announce the integration of IBM ® Watson ... to deliver targeted communications for a personalized experience. Through ... actions on their health in real time. The enhanced ... matter most to members, wherever they are in their ...
(Date:4/18/2017)... 2017  Astute Medical, Inc., developer of biomarkers for ... presented at the 2017 National Kidney Foundation (NKF) ... through April 22. Physicians will present data on two ... risk for acute kidney injury (AKI) during the management ... Elevated levels of TIMP-2 and IGFBP-7 have ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 /PRNewswire/ ... results of collaboration started in 2016, in which ... "Artificial Brain SOINN". The companies achieved initial results ... ultrasound solution by Artificial Brain SOINN. The results ... Tokyo Big Sight, April 19-21, at booths 4505 ...
Breaking Medicine Technology: